{"id":"W4405368058","doi":"10.1158/1078-0432.ccr-24-0439","title":"Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Pharmacodynamics; Adverse effect; Mesylate; Internal medicine; Pharmacology; Oncology; Pharmacokinetics; Melanoma; Cancer; Immunotherapy; Cancer research; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00124167,0.001793602,0.00169249,0.0004082783,0.000344737,0.0007901784,0.0008047344,0.000959197,0.002385],"category_scores_gemma":[0.0005248469,0.0007067126,0.000991162,0.0003243598,0.0008536099,0.0007138426,0.0002785316,0.002750227,0.0006053702],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009028075,"about_ca_system_score_gemma":0.001642832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006732778,"about_ca_topic_score_gemma":0.002012747,"domain_scores_codex":[0.9995916,0.000204183,0.00001818431,0.0000707625,0.00004709531,0.00006814828],"domain_scores_gemma":[0.9995395,0.0000537771,0.0001188672,0.0000393603,0.0000244015,0.0002240044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5552556,0.1901358,0.0118823,0.0008277959,0.001508654,0.000453442,0.0003124592,0.003563592,0.145183,0.0003761282,0.003606625,0.08689466],"study_design_scores_gemma":[0.4303921,0.541757,0.01007842,0.00002828263,0.0004549418,0.0003830896,0.00004900923,0.001343911,0.01263655,0.0001349515,0.002713981,0.00002771989],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958697,0.0007541786,0.0003444741,0.0001934052,0.00006153838,0.001541091,0.0003684999,0.00004791147,0.0008191084],"genre_scores_gemma":[0.9901952,0.001096365,0.002168727,0.0006356093,0.0001486169,0.002192894,0.001398232,0.00002576165,0.00213863],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002385,"threshold_uncertainty_score":0.007978559,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1661546502182489,"score_gpt":0.4778420161937234,"score_spread":0.3116873659754745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}